CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for OSI Pharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

OSI Pharmaceuticals, Inc.
1 Bioscience Park Dr
Phone: (302) 658-7581p:302 658-7581 FARMINGDALE, NY  11735-1019  United States Ticker: OSIPOSIP

This company was Merged or Acquired on 6/9/2010.
This company ceased filing statements with the SEC on 6/18/2010.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
OSI Pharmaceuticals, Inc. develops commercial products for the early detection, monitoring and treatment of human cancer. The Company is developing in vitro tests for the early detection, differential diagnosis, and monitoring of cancer by measuring levels of oncogene activity or oncogene-produced proteins; therapeutic products that selectively inhibit oncogene activity or selectively destroy tumor cells; and monoclonal antibodies that are specific to oncogene-encoded proteins for the localization of tumors by a process known as in vivo imaging.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/201012/31/2009YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chief Financial Officer, Executive Vice President, Treasurer PierreLegault 62 12/29/2008 12/29/2008
Executive Vice President and President - Pharmaceutical Business Kinyip GabrielLeung 59 6/1/2009 5/21/2003
Executive Vice President - Corporate Development and Strategic Planning AnkerLundemose 53 9/1/2009 2/1/2003
11 additional Officers and Directors records available in full report.

Business Names
Business Name
OSI Pharmaceuticals (UK) Limited
OSIP
Prosidion Limited

General Information
Number of Employees: 512 (As of 12/31/2009)
Outstanding Shares: 61,207,646 (As of 5/3/2010)
Shareholders: 2,590
Stock Exchange: NASD
Federal Tax Id: 133159796
Fax Number: (302) 655-5049
Email Address: kgalante@osip.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023